Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report

N Hoyle; P Zhvaniya; N Balarjishvili; D Bolkvadze; L Nadareishvili; D Nizharadze; J Wittmann; C Rohde; M Kutateladze

doi:10.1016/j.resmic.2018.05.001

Phage therapy against Achromobacter xylosoxidans lung infection in a patient with cystic fibrosis: a case report

Res Microbiol. 2018 Nov;169(9):540-542. doi: 10.1016/j.resmic.2018.05.001. Epub 2018 May 16.

Authors

N Hoyle¹, P Zhvaniya², N Balarjishvili³, D Bolkvadze³, L Nadareishvili², D Nizharadze², J Wittmann⁴, C Rohde⁴, M Kutateladze³

Affiliations

¹ Eliava Phage Therapy Center, Tbilisi, Georgia. Electronic address: Phage_therapy@pha.ge.
² Eliava Phage Therapy Center, Tbilisi, Georgia.
³ Eliava Institute of Bacteriophages, Microbiology, Virology, Tbilisi, Georgia.
⁴ Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany.

PMID: 29777836
DOI: 10.1016/j.resmic.2018.05.001

Abstract

Respiratory infections can lead to serious complications in CF patients, especially when infected with antibiotic resistant bacteria. Alternative treatments for these infections are being sought out to help address this problem. We present a clinical case of a cystic fibrosis (CF) patient, with multi-drug resistant (MDR) Achromobacter xylosoxidans chronic lung infection who was successfully managed with bacteriophage therapy.

Keywords: Achromobacter xylosoxidans; Antibiotic resistance; Bacteriophage; Cystic fibrosis; Phage therapy; Respiratory infection.

Publication types

Case Reports

MeSH terms

Achromobacter denitrificans / drug effects*
Adolescent
Anti-Bacterial Agents / pharmacology*
Cystic Fibrosis / complications*
Cystic Fibrosis / microbiology
Cystic Fibrosis / therapy
Drug Resistance, Bacterial
Female
Gram-Negative Bacterial Infections / therapy*
Humans
Lung / drug effects
Lung / microbiology
Phage Therapy*
Pneumonia, Bacterial / therapy*

Substances

Anti-Bacterial Agents